Navigation Links
Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin
Date:11/8/2011

rket basis in 2012 and 2013. Amylin will work with Lilly on all plans for markets outside the U.S. during the transition period and will guarantee that Lilly does not experience losses on exenatide-related activities during that period, up to a total cap of $60 million.

The Amylin and Lilly alliance resulted in several innovations in the diabetes market. These innovations include the 2005 launch of the first-in-class GLP-1 receptor agonist, BYETTA, a treatment that has been used by 1.8 million patients worldwide, and submission of the first once-weekly GLP-1 receptor agonist, BYDUREON, an investigational medication for type 2 diabetes designed to deliver continuous therapeutic levels of exenatide in a single weekly dose. BYDUREON received marketing authorization in the European Union in June 2011 and is currently under review in the U.S., with a Prescription Drug User Fee Action (PDUFA) date of January 28, 2012. Amylin will continue to evolve the GLP-1 market with the exenatide franchise through the development of a pen device for BYDUREON and the exenatide monthly suspension program.

Amylin to Host Investor Conference Call

Amylin will host a conference call to discuss the transition of the exenatide franchise today at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will lead the call. A slide presentation accompanying the conference call will be available through the "Investors" section of Amylin's corporate website at www.amylin.com.

The call will be webcast live through the "Investors" section of Amylin's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately 15 minutes prior to the call to register, download and install any necessary audio software. For those without access to the Inte
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Lilly CEO Says Appropriate Assessment of Both Benefits and Risks Critical in Regulatory Process
2. Lilly Foundation Commits US $30 Million to The Lilly MDR-TB Partnership
3. Lilly Provides Update on 2011 Financial Guidance Due to Xigris Withdrawal
4. Prasco® Selected as Eli Lilly and Companys Authorized Generics Partner
5. Lilly Reports Third-Quarter 2011 Results
6. Lilly Declares Fourth-Quarter 2011 Dividend
7. Lilly Announces Changes in Senior Management
8. Lilly Confirms Date and Conference Call for Third-Quarter 2011 Financial Results Announcement
9. Lilly Improves Its Environmental Footprint in Business Operations and Helps Beautify Communities
10. Eli Lilly and Company Bringing Diabetes Education Program to the Annual Legislative Conference
11. Lilly Celebrates 17th Consecutive Year as One of Working Mother 100 Best Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
(Date:7/31/2015)... N.J. and SAN DIEGO ... that its parent company Eisai Co., Ltd. (Headquarters: ... Naito , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Dr. Helen Torley , "NASDAQ: HALO") have signed ... (brand name: Halaven ® , "eribulin") in combination with ...
(Date:7/31/2015)... 31, 2015  Xencor, Inc. (NASDAQ: XNCR ), ... the treatment of autoimmune diseases, asthma and allergic diseases, ... S. Hata to its board of directors. ... corporate development is a tremendous asset to our board," ... executive officer of Xencor. "Xencor faces a range of ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... (NYSE Amex: PIP ), a biodefense company ... today that Eric I. Richman, President and Chief Executive ... Healthcare Conference being held November 29-30, 2011.  ... in one-on-one meetings at the conference.Event : , ...
... 28, 2011  CIVCO Medical Solutions is introducing RAD-GUIDE, ... at RSNA 2011. RAD-GUIDE allows physicians a method ... visualizing and adjusting planned punctures prior to needle ... to translating our expertise in ultrasound needle guidance ...
Cached Medicine Technology:PharmAthene to Present at the Piper Jaffray 23rd Annual Healthcare Conference on November 30, 2011 2CIVCO Enters CT Needle Guidance Market with RAD-GUIDE™ Launch 2
(Date:7/30/2015)... ... July 31, 2015 , ... ... By 50% or More, **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. ... 15 year veteran of helping drug, biologic and device firms reduce manufacturing errors ...
(Date:7/30/2015)... FL (PRWEB) , ... July 31, 2015 , ... On ... first meeting in Manatee county to discuss plausible solutions for controlling the heroin outbreak. ... the event of an overdose is largely perpetuating the heroin crisis in North Florida. ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, a ... app invention that can help people during emergencies. , "The worldwide mobile health ... Creative Director of World Patent Marketing. "Currently, there are about 97,000 mobile health ...
(Date:7/30/2015)... ... July 30, 2015 , ... The ... BioPharma, Inc. are pleased to announce that data standards for clinical research in ... on the CDISC website . These three Therapeutic Area (TA) standards were ...
(Date:7/30/2015)... ... , ... In an effort to provide the twenty four hour continuous care ... his practice. , The decision will also allow him to spend more time in ... his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2
... Doctors use diagnostic sonography or ultrasound to visualise organs ... researcher Koos Huijssen has developed a computer model that ... ultrasound instruments. The computer model is capable of processing ... both a PC and a parallel supercomputer. Erasmus University ...
... American Society of,Hematology (ASH), the world,s largest professional ... its Executive Committee, the,governing body of the organization. ... 2009., J. Evan Sadler, MD, PhD, will ... successive terms as president-elect and president. Charles,Abrams, MD, ...
... Nov. 4 Election Day statement by,SEIU President Andy ... Tacoma, Washington, who lost,her home and all her savings ... -- will vote today., "Samara Knight -- a ... can,t afford her mortgage payments and the,medication her son ...
... HOLLYWOOD, Calif., Nov. 4 IPC The,Hospitalist Company, Inc. ... practice company, announced today that Adam D. Singer,Chief Executive ... scheduled to present on Wednesday, November 12, 2008 at ... AZ., Event: 2008 Annual Credit Suisse ...
... Allied Minds funds research to reduce,wrinkles by developing ... a seed investment firm specializing in early stage ... Berkeley National,Laboratory through creation of start-up company, ProGDerm, ... Mina Bissell will develop a,technology based on modulation ...
... Will Sell Programming Kit and Software ,Separately From its Hearing Aids ... ... November 4, 2008 -- America Hears, Inc. , the leading ... improved version of its hearing-aid programming software, Virtual Office, and announced ...
Cached Medicine News:Health News:New Leadership Elected to the American Society of Hematology 2Health News:Today We Must Be the Change We Need 2Health News:IPC The Hospitalist Company, Inc. to Present at the 2008 Annual Credit Suisse Health Care Conference 2Health News:New Skin Rejuvenation Discovery Receives Commercial Backing 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 2Health News:America Hears Introduces New and Improved Hearing-Aid Programming Software 3
... and soft tissue reconstructions, and in ... is sometimes necessary to encourage host ... minimizing tissue attachment along another surface.,GORE ... ePTFE sheet material that offers a ...
... Repair CompanySM is pleased to announce the ... Bard Composix E/X mesh.,When Bard Composix mesh ... first ventral hernia repair prosthesis that combined ... and ePTFE, in one product. Bard Composix ...
... 1958, Bard mesh has become the standard ... Bard mesh was used by Dr. Irving ... hernia repair many years ago. Lichtenstein describes ... substance for permanent reinforcement of hernia repair. ...
... mesh is a three-dimensional, anatomically formed prosthesis ... Bard 3DMax mesh has been designed based ... the inguinal canal. The result is a ... Bard 3DMax product is constructed of Bard ...
Medicine Products: